TwoStep Therapeutics Announces Oversubscribed $62.5 Million Series A Financing and FDA Clearance of IND for First-in-Class Peptide-Drug Conjugate

TwoStep Therapeutics announced an oversubscribed $62.5 million Series A financing and FDA clearance of an IND for its first-in-class peptide-drug conjugate. The financing strengthens the private biotech's capacity to advance clinical development, while the IND clearance permits the program to enter human testing.